Oligochitosan modified albumin as plasmid DNA delivery vector: endocytic trafficking, polyplex fate, in vivo compatibility.

Cationic macromolecules condense DNA into small nanoparticles and kind polyplex. The composition of the polyplex determines the endocytic course of, the intracellular routing and the destiny of the polyplex. Beforehand, oligochitosan-modified vectors with completely different protein moieties are used as gene supply vector and the varieties of protein moiety can affect the endosome escape capability and transfection effectivity. Among the many modified vectors, oligochitosan-modified bovine serum albumin (BSA) confirmed 90% transfection efficeincy in comparison with the modified zein and ovalbumin.

These knowledge inspired us to research the mechanism of internalization concerned within the superior transfection effectivity of modified BSA/ plasmid polyplex. The impact of particular endocytic inhibitors was studied in two adherent cell traces. The caveolae-mediated and lipid-mediated pathways play a big position within the polyplex internalization. Subsequent, a colocation of polyplex with lysosome was investigated within the presence of LysoTracker utilizing confocal microscopy.

As much as 70% of polyplex efficiently escaped the lysosome with out degradation. 4 non-adherent cell traces confirmed above than 60% transfection effectivity at an optimized vector/plasmid ratio. Furthermore, no important hemolytic impact was noticed as much as 500 μg/mL of cationic BSA, indicating no detectable cell membrane disruption. General, the hybrid biomacromolecule confirmed good intracellular supply and security in a mice mannequin.

Optimization of peptide-plasmid DNA vectors formulation for gene supply in most cancers remedy exploring design of experiments.

The sphere of gene remedy nonetheless attracts nice curiosity resulting from its potential therapeutic impact in the direction of probably the most lethal ailments, equivalent to most cancers. For most cancers gene remedy to be possible and viable in a scientific setting, the design and growth of an acceptable gene supply system is crucial. Peptide primarily based vectors, particularly, disclose to be promising for therapeutic gene launch. Following this, two completely different peptides, RALA and WRAP5, have been investigated primarily relating to their capability to kind complexes with a p53 encoding plasmid (pDNA) with appropriate properties for gene supply.

To deal with this problem, and after an preliminary screening research targeted on the dependence of pDNA complexation capability with the nitrogen to phosphate teams (N/P) ratio, a design of experiments (DoE) instrument has been employed. For every peptide/pDNA system, parameters equivalent to, the buffer pH and the N/P ratio have been thought of the DoE inputs and the vector dimension, zeta potential and pDNA complexation capability (CC) have been monitored as DoE outputs. The primary purpose was to search out the optimum experimental situations to attenuate particle sizes, in addition to, to maximise the optimistic floor fees of the formulated nanosystems and maximize the pDNA CC.

By means of the DoE methodology utilized, the optimum RALA/pDNA and WRAP5/pDNA formulations have been revealed and present attention-grabbing options associated to peptide construction and pDNA complexation capability. This work illustrates the nice utility of experimental design instruments in optimizing the formulation of peptide/pDNA vectors in a minimal variety of experiments offering related data for the event of extra appropriate and environment friendly gene supply methods. The brand new insights achieved on these carriers clearly instigate deeper analysis on gene remedy.

Novel Expression Vectors Based mostly on the pIGDM1 Plasmid.

Escherichia coli is likely one of the most generally used hosts for the manufacturing of heterologous proteins. Inside this host, the selection of cloning vector constitutes a key issue for a passable amplified expression of a goal gene. We aimed to develop novel, unpatented expression vectors that allow the steady upkeep and environment friendly overproduction of proteins in E. coli. A collection of expression vectors primarily based on the ColE1-like pIGDM1 plasmid have been constructed. The vectors named pIGDMCT7RS, pIGDM4RS and pIGDMKAN carry numerous antibiotic resistance genes: chloramphenicol, ampicillin or kanamycin, respectively. Two derivatives comprise the inducible T7 promoter whereas the third one bears the constitutive pms promoter from a scientific pressure of Klebsiella pneumoniae.

 

The pIGDM1-derivatives are appropriate with different ColE1-like plasmids generally utilized in molecular cloning. The pIGDMCT7RS and pIGDM4RS vectors comprise genes encoding AGA and AGG tRNAs, which complement the scarcity of those tRNAs, growing the effectivity of synthesis of heterologous proteins. In conclusion, pIGDMCT7RS, pIGDM4RS and pIGDMKAN vectors, with considerably improved options, together with compatibility with overwhelming majority of different plasmids, have been designed and constructed. They allow a high-level expression of a desired recombinant gene and due to this fact represent a possible, precious instrument for pharmaceutical corporations and analysis laboratories for their very own analysis or for the manufacturing of recombinant biopharmaceuticals.

Minimal plasmids play a necessary position in lots of intermediate steps in molecular biology. For instance, they can be utilized to assemble constructing blocks in artificial biology or be used as intermediate cloning plasmids that are perfect for PCR-based mutagenesis strategies. A small spine additionally opens up for added distinctive restriction enzyme cloning websites. Right here we describe the technology of pICOz, a 1185-bp absolutely useful high-copy cloning plasmid with an prolonged a number of cloning web site. We imagine that that is the smallest high-copy cloning vector ever described.

Single Plasmid-Based mostly, Upgradable, and Backward-Suitable Adenoviral Vector Programs.

Current adenoviral vector methods have two drawbacks. It’s labor-intensive and time-consuming to load a transgene in these methods, and transgene-harboring vectors are lifeless ends: they can’t be reused to assemble a vector carrying one other transgene or attaining new traits. To beat these shortcomings, single plasmid-based adenoviral vector methods have been constructed the place a singular PmeI web site was positioned on the place for insertion of the exogenous gene.

OR Antibody

DF10250-100ul 100ul
EUR 280

OR Antibody

DF10250-200ul 200ul
EUR 350

Anti-c-Myc/MYC Antibody Picoband™

A00026-1 10ug
EUR 154
Description: Western blot, 0.25-0.5 μg/ml, Human, Mouse, Rat;_x000D_Flow Cytometry, 1-3 μg/1x106 cells, Human;_x000D_Direct ELISA, 0.1-0.5 μg/ml, Human

Anti- C-MYC Antibody

GWB-566932 0.2 mg Ask for price

Anti- C-MYC Antibody

GWB-9531F2 0.2 mg Ask for price

anti- c-MYC antibody

FNab01791 100µg
EUR 702
Description: Antibody raised against c-MYC

Anti-C-myc Antibody

0912-2 100ul
EUR 189
Description: Myc is a family of regulator genes and proto-oncogenes that code for transcription factors. The Myc family consists of three related human genes: c-myc (MYC), l-myc (MYCL), and n-myc (MYCN). c-myc (also sometimes referred to as MYC) was the first gene to be discovered in this family, due to homology with the viral gene v-myc. In cancer, c-myc is often constitutively (persistently) expressed. This leads to the increased expression of many genes, some of which are involved in cell proliferation, contributing to the formation of cancer. A common human translocation involving c-myc is critical to the development of most cases of Burkitt lymphoma. Constitutive upregulation of Myc genes have also been observed in carcinoma of the cervix, colon, breast, lung and stomach. Myc is thus viewed as a promising target for anti-cancer drugs. Unfortunately, Myc possesses several features that render it undruggable such that any anti-cancer drugs for Myc dysregulation will require acting on the protein indirectly, i.e. targeting the mRNA for the protein rather than a small molecule that targets the protein itself. In the human genome, C-myc is located on chromosome 8 and is believed to regulate expression of 15% of all genes through binding on enhancer box sequences (E-boxes). In addition to its role as a classical transcription factor, N-myc may recruit histone acetyltransferases (HATs). This allows it to regulate global chromatin structure via histone acetylation.

Anti-c-myc Antibody

GWB-911EAB 0.1 ml Ask for price

Anti-c-Myc Antibody

PB9092 100ug/vial
EUR 400.8

Anti-c-MYC antibody

PAab01791 100 ug
EUR 494.4

Anti-c-Myc Antibody

PA1555 100ug/vial
EUR 352.8

Anti-C-MYC Antibody

Y058202 100 µl
EUR 145

Anti-C-MYC Antibody

Y080045 100 µl
EUR 125

Anti-c-Myc Antibody

Y123314 100 µl
EUR 275

Anti-C-myc antibody

STJ160092 7 mL P
EUR 834

Anti-c-myc antibody

STJ180021 0.1 ml
EUR 282

Anti-c-Myc antibody

STJ119460 100 µl
EUR 332.4
Description: The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene.

Anti-c-Myc antibody

STJ97127 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

Anti-c-Myc antibody

STJ97962 100 µl
EUR 280.8
Description: Mouse monoclonal to c-Myc.

Anti-c-Myc antibody

STJ92355 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

Anti-c-Myc antibody

STJ92356 200 µl
EUR 236.4
Description: c-Myc is a protein encoded by the MYC gene which is approximately 48,8 kDa. c-Myc is localised to the nucleus. It is involved in signalling by NOTCH1, CDK-mediated phosphorylation and removal of Cdc6 and ERK signalling. It functions as a transcription factor that regulates transcription of specific target genes. It plays a role in cell cycle progression, apoptosis and cellular transformation. c-Myc is expressed in the nervous system, intestine, blood, liver and bone marrow. Mutations in the MYC gene may result in Burkitt lymphoma. STJ92356 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of c-Myc protein.

Anti-c-Myc antibody

STJ92357 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

Anti-c-Myc antibody

STJ92358 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

Anti-c-Myc antibody

STJ92359 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

Anti-c-myc Antibody

18824 1mg
EUR 2415

Anti-c-myc Antibody

18824-01 100ug
EUR 418

Anti-c-myc Antibody

18826-01 100ug
EUR 418

Monoclonal Anti-c-Myc Antibody Antibody

GWB-BBB026 0.1 mg Ask for price

c Myc antibody

10R-8403 100 ul
EUR 471.6
Description: Mouse monoclonal c Myc antibody

Polyclonal Antibody to C-Myc Binding Protein (MYCBP)

PAH593Hu01 100ul
EUR 245

Mouse Monoclonal Antibody to MYC

E10-31843P 100 μl
EUR 275
Description: Available in various conjugation types.

Mouse Monoclonal Antibody to MYC

MAB-606030209 0.1ml
EUR 310

Mouse Monoclonal Antibody to MYC

sAP-0559 50ug
EUR 270

Anti- C-MYC -HRP Antibody

GWB-FE1447 0.1 mg Ask for price

Anti- C-MYC -FITC Antibody

GWB-C81839 0.1 mg Ask for price

OR Conjugated Antibody

C44609 100ul
EUR 476.4

Anti- C-MYC Epitope Antibody

GWB-518893 0.1 ml Ask for price

Anti- C-MYC Epitope Antibody

GWB-8444A3 0.1 mg Ask for price

Anti-C-Myc Epitope (Myc) Tag Polyclonal Antibody

TAX162Ge01 100ul
EUR 279

Rabbit anti-c-Myc Antibody

DL90777A-100ul 100 ul
EUR 342
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL90777A-50ul 50 ul
EUR 239.4
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL90778A-100ul 100 ul
EUR 316
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL90778A-50ul 50 ul
EUR 221.2
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL95608A-100ul 100 ul
EUR 270
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL95608A-50ul 50 ul
EUR 189
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL93474A-100ul 100 ul
EUR 334
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL93474A-50ul 50 ul
EUR 233.8
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL93746A-100ul 100 ul
EUR 316
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL93746A-50ul 50 ul
EUR 221.2
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL93748A-100ul 100 ul
EUR 342
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

DL93748A-50ul 50 ul
EUR 239.4
Description: BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Rabbit anti-c-Myc Antibody

YLD2001-100ul 100 ul
EUR 320
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2001-50ul 50 ul
EUR 200
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2002-100ul 100 ul
EUR 320
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2002-50ul 50 ul
EUR 200
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2003-100ul 100 ul
EUR 320
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2003-50ul 50 ul
EUR 200
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2004-100ul 100 ul
EUR 320
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2004-50ul 50 ul
EUR 200
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2005-100ul 100 ul
EUR 320
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2005-50ul 50 ul
EUR 200
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2006-100ul 100 ul
EUR 320
Description: Rabbit polyclonal antibody to c-Myc

Rabbit anti-c-Myc Antibody

YLD2006-50ul 50 ul
EUR 200
Description: Rabbit polyclonal antibody to c-Myc

Polyclonal Anti- C-Myc Antibody

GWB-BBP431 0.1 mg Ask for price

Anti-c-Myc Monoclonal Antibody

M00026-1 100ug
EUR 476.4
Description: Rabbit Monoclonal c-Myc Antibody. Validated in WB and tested in Human, Mouse, Rat.

Anti-ATF2 (Phospho-Ser62 or 44) Antibody

43029 100ul
EUR 366

Anti-ATF2 (Phospho-Thr69 or 51) Antibody

43030 100ul
EUR 366

Anti-ATF2 (Phospho-Thr71 or 53) Antibody

43031 100ul
EUR 366

Anti-ATF2 (phospho-Thr73 or 55) Antibody

43032 100ul
EUR 366

Anti-ATF2 (phospho-Ser112 or 94) Antibody

43033 100ul
EUR 366

c-Myc Epitope (Myc) Antibody

20-abx130438
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

c-Myc Epitope (Myc) Antibody

20-abx132269
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

c-Myc Epitope (Myc) Antibody

abx132269-100tests 100 tests
EUR 850

c-Myc Epitope (Myc) Antibody

abx130438-100l 100 µl
EUR 850

c-Myc Epitope (Myc) Antibody

abx130438-1ml 1 ml Ask for price

c-Myc Epitope (Myc) Antibody

abx130438-200l 200 µl Ask for price

c-Myc(MYC275) Antibody

BNC810275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC810275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC810699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC810699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC810909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC810909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC800699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC800699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC800909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC800909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC430275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC430275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC430699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC430699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC430909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC430909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC050275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC050275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC050909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC050909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC550275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC550275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC550699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC550699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC550909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC550909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC700699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC700699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC700909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC700909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC800275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC800275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC610275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC610275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC610699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC610699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC610909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC610909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC700275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC700275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCP0275-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC275), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCP0699-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC699), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCP0909-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC909), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCR0275-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC275), RPE conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCR0699-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC699), RPE conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCR0909-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC909), RPE conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCA0275-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC275), APC conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCA0699-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC699), APC conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCA0909-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC909), APC conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCAP0275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCAP0275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCAP0699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCAP0699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCAP0909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCAP0909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCH0275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCH0275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCH0699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCH0699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCH0909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCH0909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Polyclonal TRAF3IP2 Antibody (C or N-Term)

AMM08309G 0.1 mg
EUR 580.8
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human TRAF3IP2 (C or N-Term). This antibody is tested and proven to work in the following applications:

anti- MYC tag antibody

FNab05456 100µg
EUR 658.5
Description: Antibody raised against MYC tag

anti- MYC-tag antibody

FNab05462 100µg
EUR 606.3
Description: Antibody raised against MYC-tag

Anti-c-Myc Antibody [PS00-11]

HA721182 100ul
EUR 231
Description: The proto-oncogene c-MYC is located on chromosome 8q24. It encodes a nuclear posphoprotein that acts as a growth promotor and transcription factor regulating a variety of cellular functions such as cell growth, differentiation and apoptosis. c-MYC is involved in the regulation of 10-15% of all human genes and is estimated to be involved in 20% of all human cancers. c-MYC is essential for early B-cell development in the bone marrow and the unregulated expression of c-MYC in germinal center B-cells increases the chances of oncogentic events for the development of B-cell lymphomas. Mutations, amplification, rearrangement, and translocation of the c-MyC gene have been associated with various hematopoietic tumors, leukemias, and lymphomas as well as a variety of carcinomas (e.g. thyroid, breast, endometrium) and gliomas. IHC for c-MYC overexpression (>40%) is used to screen and predict c-MYC rearrangements and distinguish diffuse large B-cell lymphoma (DLBCL) NOS from high grade B-cell lymphoma with c-MYC, BCL2 and/or BCL6 rearrangements or so-called “double or triple hit lymphomas” who tend to have aggressive behavior and poor outcome when treated with standard therapy. c-MYC protein is overexpressed in 90% of Burkitt lymphomas (BL) and caused by c-Myc gene translocation. tonsil and colon are recommended as positive and negative tissue controls for c-MYC. In the tonsil, protocols must be calibrated to provide a moderate to strong, distinct nuclear staining reaction in approximately 10% of lymphocytes scattered both in the interfollicular zones and in the reactive germinal centers of the tonsil. A weak, distinct nuclear staining reaction of mantle zone B-cells (app. 10-20%) should be seen. In colon, a weak to moderate nuclear staining reaction should be displayed in scattered epithelial cells in the basal crypts, whereas the luminal epithelial cells and smooth muscle cells of the tunica muscularis should be unstained.

Anti-C-Myc Antibody | CMYC-45A

CMYC-45A 1.0 mg
EUR 1142
Description:

Anti-C-Myc Antibody ; CMYC-45A ; Immunology Consultants Laboratory

Host: Chicken

Format: Unconjugated AP

Product Type: Primary Antibody

Antibody Clonality: Polyclonal

Anti-C-Myc Antibody | CMYC-45B

CMYC-45B 1.0 mg
EUR 1157
Description:

Anti-C-Myc Antibody ; CMYC-45B ; Immunology Consultants Laboratory

Host: Chicken

Format: Biotin Conjugated

Product Type: Primary Antibody

Antibody Clonality: Polyclonal

Anti-C-Myc Antibody | CMYC-45F

CMYC-45F 1.0 mg
EUR 1157
Description:

Anti-C-Myc Antibody ; CMYC-45F ; Immunology Consultants Laboratory

Host: Chicken

Format: FITC Conjugated

Product Type: Primary Antibody

Antibody Clonality: Polyclonal

The polymerase chain response (PCR) amplified transgene could possibly be cloned into PmeI-linearized beginning plasmids utilizing one step of Gibson meeting to generate goal adenoviral plasmids, which have been then prepared for virus rescue. This process was termed restriction meeting.

Leave a Reply

Your email address will not be published. Required fields are marked *